rs10455872
|
|
|
0.830 |
GeneticVariation |
BEFREE |
In the replication cohort, rs10455872 was also associated with CHD events (odds ratio, 1.71; 95% confidence interval, 1.14-2.57; P=0.009).
|
29703846 |
2018 |
rs10455872
|
|
G |
0.830 |
GeneticVariation |
GWASCAT |
Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
|
28753643 |
2017 |
rs10455872
|
|
|
0.830 |
GeneticVariation |
GWASCAT |
Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants.
|
24262325 |
2014 |
rs10455872
|
|
|
0.830 |
GeneticVariation |
BEFREE |
Extreme lipoprotein(a) levels or corresponding LPA KIV-2/rs10455872 risk genotypes substantially improved MI and CHD risk prediction.
|
23375930 |
2013 |
rs10455872
|
|
|
0.830 |
GeneticVariation |
BEFREE |
For the best SNP rs10455872 for plasma Lp(a) levels, the OR for CHD, CVD, and CVD death was 0.94 (95% CI: 0.69-1.28), 0.97 (0.72-1.29), and 1.23 (0.79-1.92), respectively.
|
21900290 |
2012 |
rs10455872
|
|
|
0.830 |
GeneticVariation |
GWASDB |
Large-scale gene-centric analysis identifies novel variants for coronary artery disease.
|
21966275 |
2011 |
rs3798220
|
|
|
0.820 |
GeneticVariation |
BEFREE |
Using predefined cutpoints for extreme lipoprotein(a) levels and/or corresponding LPA risk genotypes (kringle IV type 2 [KIV-2]) repeat polymorphism, rs3798220, and rs10455872 single nucleotide polymorphisms), we calculated net reclassification indices from <10% to 10% to 19.9% to ≥20% absolute 10-year MI and CHD risk.
|
23375930 |
2013 |
rs3798220
|
|
|
0.820 |
GeneticVariation |
BEFREE |
Single nucleotide polymorphisms (SNPs) at the KIF6 (kinesin like protein 6, rs20455 or 719Arg), LPA (lipoprotein(a), rs3798220), TAS2R50 (taste receptor type 2, member 50, rs1376251) and VAMP8 (vesicle-associated membrane protein 8, rs1010) have previously been associated with low density lipoprotein cholesterol (LDL-C) lowering response to statins, coronary heart disease (CHD) at baseline, or CHD events on trial.
|
22192511 |
2012 |
rs3798220
|
|
C |
0.820 |
GeneticVariation |
GWASCAT |
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease.
|
21378990 |
2011 |
rs3798220
|
|
|
0.820 |
GeneticVariation |
GWASDB |
Large-scale gene-centric analysis identifies novel variants for coronary artery disease.
|
21966275 |
2011 |
rs3798220
|
|
C |
0.820 |
GeneticVariation |
GWASDB |
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease.
|
21378990 |
2011 |
rs7767084
|
|
|
0.710 |
GeneticVariation |
BEFREE |
However, our meta-analysis indicated that rs7767084</span> is not associated with a higher ri</span>sk of CHD.
|
23653095 |
2013 |
rs7767084
|
|
T |
0.710 |
GeneticVariation |
GWASCAT |
Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease.
|
19198611 |
2009 |
rs10755578
|
|
G |
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease.
|
19198611 |
2009 |
rs10755578
|
|
C |
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease.
|
19198611 |
2009 |